Positions

Overview

  • Dr. de Andrade completed his medical degree in 1990 at the Federal University of Rio Grande do Sul (UFRGS) in Porto Alegre, Brazil. He went on to complete a residency in Internal Medicine at Hospital de Clinicas de Porto Alegre (UFRGS) where he also served as Chief Medical Resident. He came to the United States in 1994 and completed a residency in Internal Medicine at the University of Miami/Jackson Memorial Hospital and subsequently a fellowship in pulmonary and critical care medicine at the University of Alabama at Birmingham (UAB). He joined the faculty at UAB in 2000 and has risen to the rank of Associate Professor of Medicine. Dr. de Andrade established the UAB Interstitial Lung Disease (ILD) Program and serves as the Medical Director of the Medical ICU at the Birmingham VA Medical Center. In 2013 he was appointed Director of the Pulmonary Disease and Critical Care Medicine Fellowship Program.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry.  Respiratory Research.  23. 2022
    2022 Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.  BMC Pulmonary Medicine.  22. 2022
    2022 Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease: Data From the Pulmonary Fibrosis Foundation Patient Registry.  Chest.  162:603-613. 2022
    2022 Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study.  Chest.  162:145-155. 2022
    2022 Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort 2022
    2022 Correction to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort (Lung, (2022), 200, 1, (11-18), 10.1007/s00408-021-00505-y) 2022
    2022 Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative.  Chest.  161:470-482. 2022
    2022 Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis 2022
    2021 Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry.  Respiratory Medicine.  189. 2021
    2021 Idiopathic pulmonary fibrosis: Exploring the clinical and economic implications of the evolving treatment landscape.  American Journal of Managed Care.  27:S131-S137. 2021
    2021 Citrullinated vimentin mediates development and progression of lung fibrosis.  Science Translational Medicine.  13. 2021
    2021 Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib.  Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine.  15. 2021
    2020 The pulmonary fibrosis foundation patient registry: Rationale, design, and methods.  Annals of the American Thoracic Society.  17:1620-1628. 2020
    2020 Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: A Delphi consensus study.  BMC Pulmonary Medicine.  20. 2020
    2020 Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry.  BMJ Open Respiratory Research.  7. 2020
    2020 Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry.  Chest.  157:1522-1530. 2020
    2020 Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry.  Chest.  157:1188-1198. 2020
    2020 Assessment of viral RNA in idiopathic pulmonary fibrosis using RNA-seq.  BMC Pulmonary Medicine.  20. 2020
    2020 The senescence-associated matricellular protein CCN1 in plasma of human subjects with idiopathic pulmonary fibrosis.  Respiratory Medicine.  161. 2020
    2019 Preoperative Evaluation of Patients With Interstitial Lung Disease.  Chest.  156:826-833. 2019
    2019 Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry.  Respiratory Research.  20. 2019
    2019 Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients.  PLoS One.  14. 2019
    2019 Home-Based Pulmonary Rehabilitation for Patients With Idiopathic Pulmonary Fibrosis: A PILOT STUDY.  Journal of Cardiopulmonary Rehabilitation and Prevention.  39:281-284. 2019
    2019 Predicting outcome in idiopathic pulmonary fibrosis: Addition of fibrotic score at thin-section ct of the chest to gender, age, and physiology score improves the prediction model 2019
    2019 Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: Insights from the IPF-PRO Registry.  Respiratory Research.  20. 2019
    2019 Patient registries in idiopathic pulmonary fibrosis.  American Journal of Respiratory and Critical Care Medicine.  200:160-167. 2019
    2019 Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis.  American Journal of Respiratory and Critical Care Medicine.  200:199-208. 2019
    2019 Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis 2019
    2018 Pharmacological management of progressive-fibrosing interstitial lung diseases: A review of the current evidence.  European Respiratory Review.  27. 2018
    2017 Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.  European Respiratory Review.  26. 2017
    2017 Autoimmunity to vimentin is associated with outcomes of patients with idiopathic pulmonary fibrosis.  Journal of Immunology.  199:1596-1605. 2017
    2017 More than meets the eye: IgG4-related disease presenting as isolated interstitial lung disease.  Rheumatology.  56:1630-1631. 2017
    2017 Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: An international case-cohort study.  European Respiratory Journal.  50. 2017
    2017 Erratum: 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs (JCI Insight. (2017) 2:2 (e91377) DOI: 10.1172/jci.insight.91377).  JCI Insight.  2. 2017
    2017 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs..  JCI Insight.  2:e91377. 2017
    2017 What is in a pattern? that which we call idiopathic pulmonary fibrosis by any other pattern would behave alike!.  American Journal of Respiratory and Critical Care Medicine.  195:10-12. 2017
    2016 Alveolar epithelial disintegrity in pulmonary fibrosis 2016
    2016 A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival.  Respiratory Medicine.  115:33-38. 2016
    2016 FG-3019 anti-connective tissue growth factor monoclonal antibody: Results of an open-label clinical trial in idiopathic pulmonary fibrosis.  European Respiratory Journal.  47:1481-1491. 2016
    2016 Oxidative modifications of protein tyrosyl residues are increased in plasma of human subjects with interstitial lung disease.  American Journal of Respiratory and Critical Care Medicine.  193:861-866. 2016
    2015 The idiopathic pulmonary fibrosis clinical research network (IPFnet): Diagnostic and adjudication processes.  Chest.  148:1034-1042. 2015
    2015 Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis.  Journal of Translational Medicine.  13. 2015
    2014 Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.  Respiratory Medicine.  108:181-188. 2014
    2014 Development and maintenance of a biospecimen repository for clinical samples derived from pulmonary patients.  Clinical and Translational Science.  7:336-341. 2014
    2014 Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.  New England Journal of Medicine.  370:2093-2101. 2014
    2013 Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial.  European Respiratory Journal.  42:1622-1632. 2013
    2013 Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.  Respiratory Research.  14. 2013
    2013 Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial.  ACP journal club.  158:641-649. 2013
    2012 Idiopathic Pulmonary Fibrosis.  Immunology and Allergy Clinics of North America.  32:473-485. 2012
    2012 A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.  American Journal of Respiratory and Critical Care Medicine.  186:88-95. 2012
    2011 Acute exacerbations of interstitial lung disease.  Clinical Pulmonary Medicine.  18:113-118. 2011
    2010 A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.  New England Journal of Medicine.  363:620-628. 2010
    2010 Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.  American Journal of Respiratory and Critical Care Medicine.  181:604-610. 2010
    2009 Innovative approaches to the therapy of fibrosis.  Current Opinion in Rheumatology.  21:649-655. 2009
    2009 Soluble P-selectin and the risk of primary graft dysfunction after lung transplantation.  Chest.  136:237-244. 2009
    2008 BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.  American Journal of Respiratory and Critical Care Medicine.  177:75-81. 2008
    2007 Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation.  American Journal of Transplantation.  7:2573-2578. 2007
    2007 Thoughts on the diagnosis and management of interstitial lung diseases.  Southern Medical Journal.  100:555-556. 2007
    2007 Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction.  American Journal of Respiratory and Critical Care Medicine.  175:69-74. 2007
    2001 Association of reactive nitrogen species metabolites, myeloperoxidase, and airway inflammation in lung transplants.  Journal of Investigative Medicine.  49:166-172. 2001
    2000 Protein nitration, metabolites of reactive nitrogen species, and inflammation in lung allografts.  American Journal of Respiratory and Critical Care Medicine.  161:2035-2042. 2000
    1999 The lung in systemic lupus erythematosus 1999

    Research Overview

  • Because of his related interest in ILD, Dr. de Andrade has developed a strong clinical research program to study novel therapies for IPF. The UAB Interstitial Lung Disease Program was part of the NIH/NHLBI (IPFnet), which was a network of specialized centers across the country formed by the NIH in order to develop better treatments for IPF. Dr. de Andrade served on a number of committees of the IPFnet and is the Chair of the Steering Committee of the Diffuse and Interstitial Lung Disease Network of the American College of Chest Physicians. He is also a member of the Nominating Committee of the Assembly of Clinical Problems of the American Thoracic Society. He is the Director of the UAB Site of the Pulmonary Fibrosis Foundation Clinical Care Network and he also serves on the Network’s Steering Committee. Dr. de Andrade is the Principal Investigator for the UAB Pulmonary Translational Research and Clinical Database (PTREC)/Pulmonary Biospecimen Repository (in collaboration with Drs. Steven Duncan and Amit Gaggar) which aims to support UAB's clinical and translational research programs.

    • Principal Investigator On

  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital
  • Anti-Coagulant Effectiveness in Idiopathic Pulmonary Fibrosis  awarded by Duke University
  • Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF_Pro)  awarded by Duke University
  • Prednisone, Azathioprine, N-acetylcysteine: A Study That Evaluates Response in Idiopathic Pulmonary Fibrosis, A Randomized, Double-Blind, Placebo Controlled Trial (PANTHER-IPF)  awarded by Duke University
  • Private Grant  awarded by INTERMUNE, INC.
  • Private Grant  awarded by ACTELION CLINICAL RESEARCH, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd.
  • Private Grant  awarded by JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by IMMUNEWORKS
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by FIBROGEN, INC.
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd.
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by INTERMUNE, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by FIBROGEN, INC.
  • Private Grant  awarded by MedImmune
  • Private Grant  awarded by VERILOGUE, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by INTERMUNE, INC.
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan
  • UAB Interstitial Lung Disease Program  awarded by Pulmonary Fibrosis Foundation

    • Investigator On

  • Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Frailty as an Outcome Measure in Idiopathic Pulmonary Fibrosis  awarded by Pulmonary Fibrosis Foundation
  • Idiopathic Pulmonary Fibrosis, A Disease Initiated by Mucociliary Dysfunction  awarded by UNIVERSITY OF COLORADO DENVER - NEW
  • Molecular Pathogenesis and Phenotype of Acquired CFTR Dysfunction in COPD  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by MedImmune
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by MALLINCKRODT ARD, INC
  • Private Grant  awarded by BIOGEN MA INC
  • Rituximab Therapy in Patients with IPF  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease - Project One: A Phase IIB Clinical Trial of the Safety and Efficacy of a NOX1/4 Inhibitor in IPF  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease: Core C - Clinical Core  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS

    • Education And Training

  • Federal University of Rio Grande do Sul (UFRGS), Residency
  • Federal University of Rio Grande do Sul (UFRGS), Residency
  • Hospital de Clínicas de Porto Alegre, Residency
  • University of Miami/Jackson Memorial Hospital, Residency
  • University of Miami/Jackson Memorial Medical Center, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • University of Alabama at Birmingham Pulmonary, Allergy, and Critical Care Medicine, Postdoctoral Fellowship

    • Full Name

  • Joao De Andrade